Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Binge Eating Disorder Overview 6 Therapeutics Development 7 Pipeline Products for Binge Eating Disorder - Overview 7 Binge Eating Disorder - Therapeutics under Development by Companies 8 Binge Eating Disorder - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Unknown Stage Products 12 Binge Eating Disorder - Products under Development by Companies 13 Binge Eating Disorder - Companies Involved in Therapeutics Development 14 Heptares Therapeutics Limited 14 Omeros Corporation 15 Opiant Pharmaceuticals, Inc. 16 Polleo Pharma Limited 17 Sunovion Pharmaceuticals Inc. 18 Teva Pharmaceutical Industries Ltd. 19 Binge Eating Disorder - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 28 armodafinil - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 dasotraline hydrochloride - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 naloxone hydrochloride - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 OMS-527 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecules for Binge Eating Disorder - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Binge Eating Disorder - Recent Pipeline Updates 38 Binge Eating Disorder - Dormant Projects 42 Binge Eating Disorder - Discontinued Products 43 Binge Eating Disorder - Product Development Milestones 44 Featured News & Press Releases 44 Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline 44 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 45 Disclaimer 46

List of Tables Number of Products under Development for Binge Eating Disorder, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Comparative Analysis by Unknown Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Binge Eating Disorder - Pipeline by Heptares Therapeutics Limited, H1 2016 14 Binge Eating Disorder - Pipeline by Omeros Corporation, H1 2016 15 Binge Eating Disorder - Pipeline by Opiant Pharmaceuticals, Inc., H1 2016 16 Binge Eating Disorder - Pipeline by Polleo Pharma Limited, H1 2016 17 Binge Eating Disorder - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016 18 Binge Eating Disorder - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 27 Binge Eating Disorder Therapeutics - Recent Pipeline Updates, H1 2016 38 Binge Eating Disorder - Dormant Projects, H1 2016 42 Binge Eating Disorder - Discontinued Products, H1 2016 43 List of Figures Number of Products under Development for Binge Eating Disorder, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Top 10 Targets, H1 2016 21 Number of Products by Stage and Top 10 Targets, H1 2016 21 Number of Products by Top 10 Mechanism of Actions, H1 2016 23 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 23 Number of Products by Routes of Administration, H1 2016 25 Number of Products by Stage and Routes of Administration, H1 2016 25 Number of Products by Stage and Molecule Types, H1 2016 27

Heptares Therapeutics Limited Omeros Corporation Opiant Pharmaceuticals, Inc. Polleo Pharma Limited Sunovion Pharmaceuticals Inc. Teva Pharmaceutical Industries Ltd.